Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Lymphoid 1

Conditions

Lymphoma, Follicular 1Hemophilia A 1

Interventions

Rituximab 1402Cyclophosphamide 1308Vincristine 670Doxorubicin 589Etoposide 527Prednisone 512Cytarabine 487fludarabine 470Methotrexate 446Dexamethasone 414fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 283Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 164Magnetic Resonance Spectroscopy 157Calcium Dobesilate 151

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Factor VIII × Lymphoid × Clear all
NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡